Document is current

Article History

Received: 28 December 2022

Accepted: 20 November 2023

First Online: 29 November 2023

Declarations

:

: Our study was designed as a sub analysis from a national multicenter study (ReumaCoV-Brazil) with the idealization, support, and supervision of the Brazilian Society of Rheumatology during the emergency period of the COVID-19 pandemic and with the Federal University of Pernambuco as the coordinating center and managing of ethical demands. The central and original project was approved by CONEP (CAAE 30186820.2.1001.8807) on April 5, 2020.The research team contacted all patients identified by the eligibility criteria by telephone, giving initial authorization and permission for the collection of clinical information. When the restrictions of the pandemic allowed face-to-face consultation in the respective center, they all read and signed the consent form.As mentioned above, we used the same database of patients that had already been approved by CONEP as an unfolding. We emphasize that there is no need for further collection of clinical or laboratory data because the HLA-B27 positivity and evaluation with the metrics used in the study are part of the follow-up routine of patients with spondyloarthritis.In addition, it is important to emphasize that the original ReumaCoV-Brazil study was conceived and developed in full pandemic context, with restrictions for face-to-face medical evaluations and logistical difficulties, in view of the sanitary recommendations of social distancing. Thus, many data needed to be collected by telephone and by searching for previous information, retrospectively, in the patient’s electronic medical record (PEP), with prospective updates on the outcomes of the evolution of COVID-19 and disease activity.

: The authors agreed with the publication.

: Not applicable.